Employing artificial intelligence for optimising antibiotic dosages in sepsis on intensive care unit: a study protocol for a prospective observational study (KI.SEP)
Authors:
- Britta MarkoBMBritta Marko
- Lars PalmowskiLPLars Palmowski
- Hartmuth NowakHNHartmuth Nowak
- Andrea WitowskiAWAndrea Witowski
- Björn KoosBKBjörn Koos
- Katharina RumpKRKatharina Rump
- Lars BergmannLBLars Bergmann
- Julia BandowJBJulia Bandow
- Martin EisenacherMEMartin Eisenacher
- Patrick GüntherPGPatrick Günther
- Michael AdamzikMAMichael Adamzik
- Barbara SitekBSBarbara Sitek
Open Access
Abstract
Introduction In sepsis treatment, achieving and maintaining effective antibiotic therapy is crucial. However, optimal antibiotic dosing faces challenges due to significant variability among patients with sepsis. Therapeutic drug monitoring (TDM), the current gold standard, lacks initial dosage adjustments and global availability. Even with daily TDM, antibiotic serum concentrations (ASCs) often deviate from the therapeutic range. This study addresses these challenges by developing machine learning (ML)-based ASC prediction models capable of handling variable data input and encompassing diverse clinical, laboratory, microbiological and proteomic parameters without the need for daily TDM. Methods This prospective observational study is conducted in a German university hospital intensive care unit. Eligible sepsis patients receive continuous antibiotic therapy with piperacillin/tazobactam (n=100) or meropenem (n=100) within 24 hours. Exclusion criteria include refusal, pregnancy, lactation and severe anaemia (haemoglobin Ethics and dissemination The study received approval from the Ethics Committee of the Medical Faculty of Ruhr-University Bochum (No. 23-7905). Findings will be disseminated through open-access publication in a peer-reviewed journal and social media channels. Trial registration number DRKS00032970.Keywords
Funding Information
- Land Nordrhein-Westfalen (IN-2-08E)
This publication has 22 references indexed in Scilit:
- Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trialIntensive Care Medicine, 2022
- Predicting Missing Values in Medical Data Via XGBoost RegressionJournal of Healthcare Informatics Research, 2020
- Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#Intensive Care Medicine, 2020
- Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease StudyThe Lancet, 2020
- Pharmacokinetics/Pharmacodynamics of β-Lactams and Therapeutic Drug Monitoring: From Theory to Practical Issues in the Intensive Care UnitSeminars in Respiratory and Critical Care Medicine, 2019
- Early target attainment of continuous infusion piperacillin/tazobactam and meropenem in critically ill patients: A prospective observational studyJournal of Critical Care, 2019
- The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infectionsIntensive Care Medicine, 2017
- Assessment of Clinical Criteria for SepsisJAMA, 2016
- Antimicrobial Pharmacokinetic and Pharmacodynamic Issues in the Critically Ill with Severe Sepsis and Septic ShockCritical Care Clinics, 2011
- Continuous infusion of β-lactam antibiotics in severe infections: a review of its roleInternational Journal of Antimicrobial Agents, 2007